8-K: Profound Medical Corp. Aims to Establish TULSA-PRO as Mainstream Prostate Treatment Option

Profound Medical Corp. is positioning its TULSA-PRO system as a leading treatment for prostate ablation, both for malignant and benign conditions, highlighting clinical trial results, patient satisfaction, and new AI-powered software enhancements.

Summary

• Profound Medical Corp. is focused on establishing TULSA-PRO as a mainstream treatment for personalized prostate ablation, addressing both prostate cancer and benign prostatic hyperplasia (BPH).
• The company highlights the CAPTAIN Level 1 randomized controlled trial, which compares TULSA to robotic prostatectomy, emphasizing peri-operative data and patient experience.
• A new TULSA-PRO software with the TULSA-AI Volume Reduction module and Treatment ARC is being unveiled, targeting the BPH market.
• The TULSA+ program aims to break barriers to MRI access with a new commercial model, evolving towards true image-guided incision-free surgery.
• Clinical data from the CAPTAIN trial shows TULSA improves patient peri-operative outcomes compared to robotic prostatectomy, with no blood loss, no overnight hospital stay, less pain, and less interference with activities.
• Patient satisfaction is high with TULSA, leading to increased patient demand and adoption.
• The TULSA-AI Contouring Assistant, FDA cleared in May 2024, is being enhanced with TULSA-AI Volume Reduction for BPH treatment.
• A Phase I-II study of TULSA-PRO for BPH showed improved IPSS, QoL, flow, and PVR, with prostate volume decreasing from 56 to 31 cc.
• The company is targeting a total addressable market (TAM) of approximately $5 billion, with 70% in recurring revenue, by addressing both malignant prostate tissue ablation (200,000 patients per year) and BPH (400,000 patients per year).

Sentiment

Score: 8

Explanation: The document presents a positive outlook for Profound Medical, highlighting clinical trial results, new product launches, and market opportunities. The focus on improved patient outcomes and a large addressable market suggests strong growth potential.

Positives

• TULSA-PRO demonstrates improved peri-operative outcomes compared to robotic prostatectomy, including no blood loss and no overnight stay.
• Patients report less pain and faster recovery with TULSA-PRO.
• High patient satisfaction is driving demand and adoption of TULSA-PRO.
• The TULSA-AI Volume Reduction module expands the applicability of TULSA-PRO to BPH treatment.
• The TULSA+ program aims to improve MRI access and affordability, potentially increasing the number of patients who can benefit from the technology.
• Clinical data supports the safety and efficacy of TULSA-PRO for both prostate cancer and BPH.

Negatives

• The CAPTAIN trial is still ongoing, and the final results comparing TULSA-PRO to robotic prostatectomy are not yet available.
• The adoption of TULSA-PRO requires urologists to learn MRI and control the MRI-based surgical suite, which may present a barrier to entry.
• The cost and availability of MRI time and anesthesia support may limit the accessibility of TULSA-PRO in some locations.

Risks

• The success of TULSA-PRO depends on the results of the CAPTAIN trial, which could impact insurance coverage and adoption.
• Competition from other prostate cancer and BPH treatments could limit the market share of TULSA-PRO.
• Reimbursement rates for TULSA-PRO procedures may vary across different regions and insurance providers.
• The company's ability to scale up production and distribution of TULSA-PRO systems may be affected by supply chain disruptions or other unforeseen events.

Future Outlook

Profound Medical aims to establish TULSA-PRO as the mainstream treatment option for personalized prostate ablation, both for malignant and benign conditions, by leveraging clinical evidence, AI-powered software enhancements, and the TULSA+ program to improve MRI access and affordability.

Management Comments

• Guest speakers' presentations reflect the medical views and experience of the physicians and are not attributable to Profound Medical.

Industry Context

The announcement positions Profound Medical within the growing market for minimally invasive prostate treatments, competing with established options like robotic prostatectomy and emerging technologies for BPH. The focus on MRI-guided precision and AI-enhanced workflows aligns with the broader trend towards personalized medicine and image-guided interventions.

Comparison to Industry Standards

• Robotic prostatectomy, while improving peri-operative outcomes like blood loss and length of stay compared to open surgery, has not significantly improved urinary continence, erectile dysfunction, or decision regret.
• TULSA-PRO aims to address these limitations by offering a less invasive approach with potentially better functional outcomes.
• The TACT trial showed promising results for TULSA-PRO, with 87% of patients reporting erections sufficient for penetration and 92% pad-free at 5 years, which compares favorably to some studies of robotic prostatectomy.
• For BPH treatment, TULSA-PRO is positioned as an alternative to procedures like TURP, HoLEP, and UroLift, particularly for patients with large prostates or those seeking to preserve sexual function.
• A Phase I-II study of TULSA-PRO for BPH showed comparable improvements in IPSS and QoL to other BPH treatments, with the added benefit of no hospital stay or post-operative bleeding.

Stakeholder Impact

• Shareholders: Potential for increased stock value due to positive clinical data and market expansion.
• Patients: Access to a less invasive prostate treatment option with improved outcomes.
• Physicians: Opportunity to offer a new and innovative treatment option to their patients.
• Hospitals: Potential to generate revenue through TULSA-PRO procedures and MRI services.

Next Steps

• Continue the CAPTAIN randomized trial comparing TULSA to radical prostatectomy.
• Collect clinical data with the CARE registry.
• Position TULSA-AI Volume Reduction for patients with larger prostates and/or higher PSAs.
• Streamline TULSA-PRO procedures to a consistent 60-90 minutes total procedure time.

Key Dates

Keywords

TULSA-PRO, prostate cancer, BPH, MRI-guided, ablation, CAPTAIN trial, robotic prostatectomy, TULSA-AI, volume reduction, interventional MRI